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platelet reactivity after a 1-week statin wash-out period entered the
PEARL trial. Patientswere randomly assigned to atorvastatin (20 mg day,
N= 50) or rosuvastatin (10 mg day, N= 50) for 30 days. After another
1-week wash-out period to avoid any carryover effect, cross-over was
performed, and patients were switched to the other drug which was
continued for 30 days. Platelet reactivity (expressed as P2Y(12) reaction
units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San
Diego, California]) was measured before and at the end of each 30-day
treatment period. High platelet reactivity after clopidogrel was deﬁned
as a PRU value N 208.
Results: After the 30-day treatment with atorvastatin, platelet
reactivity did not signiﬁcantly change as compared with baseline,
pre-treatment evaluation (119 ± 66 vs 136 ± 59 PRU, NS), with 2
patients only showing a PRU N 208. Similarly, after 30-day treatment
with rosuvastatin, platelet reactivity was unchanged as compared
with baseline (135 ± 46 vs 128 ± 62 PRU, NS), with PRU N 208
occurring in 3 patients.
Conclusion: Atorvastatin does not negatively affect DAPT as com-
pared with rosuvastatin when is given to stable CAD patients with
baseline normal platelet reactivity while on DAPT. (ClinicalTrials.gov
Identiﬁer: NCT01567774).
doi:10.1016/j.ijcme.2015.05.018
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Background: Levels of platelet reactivity in patients on dual
antiplatelet therapy (DAPT) can be inﬂuenced by concomitant
treatment with medications (i.e. statins) that inhibit the CYP3A4
system involved in the activation of clopidogrel. Atorvastatin and
simvastatin are metabolized by CYP3A4, while pitavastatin is mostly
excreted unchanged in bile and undergoes minimal biotransforma-
tion through the cytochrome P450 system. The primary objective of
this study was to compare the pharmacodynamic effects of a
CYP3A4-metabolized statin (atorvastatin) versus a non-CYP3A4-
metabolized statin (pitavastatin) in patients with coronary artery
disease (CAD) treated with DAPT.
Methods: A total of 102 CAD patients receiving DPAT (clopidogrel
75 mg plus aspirin 100 mg) after percutaneous coronary interven-
tion entered the PORTO trial. After a 1-week statin wash-out period,
patients were randomly assigned to atorvastatin (20 mg day,
N = 51) or pitavastatin (4 mg day, N = 51) for 30 days. After
another 1-week wash-out period to avoid any carryover effect,
cross-over was performed, and patients were switched to the other
drug which was continued for 30 days. Platelet reactivity (expressed
as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow
assay [Accumetrics, San Diego, California]) was measured before and
at the end of each 30-day treatment period. High platelet reactivity
after clopidogrel was deﬁned as a PRU value N 208.
Results: After the 30-day treatment period with atorvastatin,
platelet reactivity was signiﬁcantly higher as compared with pre-
treatment values (212 ± 96 vs 166 ± 79 PRU, p = 0.010), with a
more common occurrence of patients showing a PRU N 208 (57% vs.
35%, p = 0.047). Conversely, after the 30-day treatment period with
pitavastatin, platelet reactivity was unchanged as compared with
pre-treatment values (178 ± 81 vs 189 ± 73 PRU, NS), with no
difference in the frequency of patients showing a PRU N 208 before
and after treatment (41% vs. 37%, NS).
Conclusion: Pitavastatin, a non-CYP3A4-metabolized statin, does
not negatively affect DAPT as compared with atorvastatin in CAD
patients on DAPT. (ClinicalTrials.gov Identiﬁer: NCT01648829).
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Introduction: Cardiovascular prevention include a class I indication to
statins in addition to non-pharmacologic intervention and prevention
strategies in patients deemed to be ‘high risk’ according to current
scientiﬁc guidelines. In the real world, however, statin treatment is often
discontinued due to side effects. In addition, statins are not indicated in
those subjects deemed to be ‘low risk’, inwhomonly non-pharmacologic
intervention and prevention strategies are currently prescribed. Along
with non-pharmacologic intervention and prevention strategies, newer
approaches to reduce cholesterol blood levels currently include
nutraceuticals, which are compounds derived from foods with choles-
terol lowering actions. The primary objective of this study is twofold:
First, to prospectively compare in the real world clinical practice the
efﬁcacy and tolerability of non-pharmacologic intervention vs. the
combination of non-pharmacologic intervention with a nutraceutical-
based protocol in patients inwhom statin treatment is not tolerated or is
not indicated. Second, to evaluate gender and race/ethnic differences in
the hypolipidemic effects of a nutraceutical-based protocol among
European countries.
Methods: Class I indication to receive statin treatment but previous
(b12 months) withdrawn of a statin due to side effects and unwilling to
receive treatment with an alternative statin. Class I indication to receive
non-pharmacologic intervention and prevention strategies because of
hyperlipidemia with ‘low risk’ classiﬁcation.
Patients will be assigned at the discretion of their own general
practitioner to receive for 1 year either non-pharmacologic inter-
vention and prevention strategies or non-pharmacologic interven-
tion and prevention strategies associated with a commercially
available nutraceutical combined pill (1 capsule/day containing red
yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
Primary outcome included reasons for treatment discontinuation
use and secondary outcomes included plasma lipids levels.
Results: At entry, 51 patients were randomized to ezetimibe and 50
to placebo. Baseline clinical features and lipid proﬁles were similar
between groups. During the 1-year trial, 5 patients of the nutraceutical-
group stopped the pill due to myalgia whereas in the ezetimibe group 4
patients had gastrointestinal intolerance and 3 had fatigue and dizziness
(NS). At 1-year evaluation, levels of triglyceride, creatine kinase or liver
enzymes were similar between groups. Conversely, total cholesterol
level (205 ± 31 vs 241 ± 41 mg/dl, p = 0.001) and LDL cholesterol
(105 ± 31 vs 131 ± 41 mg/dl, p = 0.001) were signiﬁcantly lower in
the nutraceutical-group than in the ezetimibe-group.
Conclusions: A combination of nutraceuticals with lipid-lowering
biological activity can signiﬁcantly decrease cholesterol levels
without causing clinical or metabolic side effects and is more
effective than ezetimibe 10 mg/day in statin-intolerant patients
treated with PCI. (ClinicalTrials.gov Identiﬁer: NCT01649986).
doi:10.1016/j.ijcme.2015.05.020
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